Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.
Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
Codiak BioSciences, Inc. (CDAK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance. Stock up
United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.
The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers....